Status:
COMPLETED
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
Lead Sponsor:
Novartis
Conditions:
Parkinson's Disease
L-dopa Induced Dyskinesia
Eligibility:
All Genders
30-85 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
Eligibility Criteria
Inclusion
- Patients with Parkinson's Disease
- Patients with L-dopa induced dyskinesia for at least 3 months
- Patients with L-dopa treatment for at least 3 years, stable for 1 month minimum
Exclusion
- History of severe allergy to food or drugs
- Very low or high body weight.
- Prior surgery for Parkinson's Disease
- Smokers Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00888004
Start Date
March 1 2009
Last Update
April 19 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Dresden, Germany
2
Novartis Investigative Site
Kassel, Germany
3
Novartis Investigative Site
Leun-Biskirchen, Germany
4
Novartis Investigative Site
Marburg, Germany